Chemical and Pharmaceutical Bulletin · 2005 · 12 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationStructure-activity RelationshipsDrug-receptor InteractionsLigand BindingLigand-based DesignPotency OptimizationReceptor PharmacologyBinding AssaysLead Compound OptimizationMuscarinic Receptor AntagonismMuscarinic Receptor PharmacologyMuscarinic Receptor SubtypesMuscarinic ReceptorsReceptor Binding AssaysSolution-phase Parallel Synthesis
Synthesis and structure-activity relationship of a new class of muscarinic M(3) selective antagonists were described. In the course of searching for a muscarinic M(3) antagonist with a structure distinct from those of the 2-(4,4-difluorocyclopentyl)-2-phenylacetamide derivatives, we identified a thiazole-4-carboxamide derivative (1) as a lead compound in our in-house chemical collection. Since this compound (1) showed relatively low binding affinity (K(i)=140 nM) for M(3) receptors in the human binding assays, we tried to improve its potency and selectivity for M(3) over M(1) and M(2) receptors by derivatization of 1 through a combinatorial approach. A solution-phase parallel synthesis effectively contributed to the optimization of each segment of 1. Thus, we have identified a cyclooctenylmethyl derivative (3e) and a cyclononenylmethyl derivative (3f) as representative M(3) selective antagonists in this class.
15
Identification of a Family of Muscarinic Acetylcholine Receptor Genes
Tom I. Bonner, Noel J. Buckley, Alice C. Young et al. · Science · 1987 · 1.4K citations
Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes
Tom I. Bonner, Alice C. Young, Mark R. Bran et al. · Neuron · 1988 · 791 citations · Full text